94 th Vifor Pharma Group Annual General Meeting
Regulatory News:
At today’s 94th Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. The Annual General Meeting was again held in accordance with the Ordinance 3 and the COVID-19 Act and has been reconfirmed in view of the current status of the tender offer launched by CSL Behring AG. Shareholders exercised their rights exclusively through the independent proxy.
Shareholder approvals
Shareholders approved the Annual Report and the Annual Financial Statements of Vifor Pharma Ltd. and the consolidated Financial Statements of Vifor Pharma for 2021 by a large majority, as well as the 2021 Remuneration Report in a consultative vote. In addition, shareholders discharged the members of the Board of Directors and the Executive Committee for the business year 2021. A dividend of CHF 2.00, as proposed by the Board of Directors, was approved and will be paid to shareholders from 3 May 2022 on.
Re-election of Board of Directors
The Annual General Meeting confirmed Chairman Jacques Theurillat and the other members of the Board of Directors, Prof. Hon. Dr. Michel Burnier, Dr. Romeo Cerutti, Dr. Alexandre LeBeaut, Dr. Sue Mahony, Åsa Riisberg and Kim Stratton in office, as well as Dr. Sue Mahony (Chair), Prof. Hon. Dr. Michel Burnier and Dr. Romeo Cerutti to the Remuneration Committee.
Conditional new elections to the Board, effective as from settlement date
In addition, the Annual General Meeting conditionally elected Paul McKenzie (elected Chairman), Greg Boss, John Levy, Joy Linton, Markus Stämpfli and Elizabeth Walker as new members of the Board of Directors, to become effective as from the date of settlement under the terms of the tender offer of CSL Behring AG as of 18 January 2022. Greg Boss, Joy Linton and Elizabeth Walker have been conditionally elected to the Remuneration Committee.
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency and nephrology. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions across iron, dialysis, nephrology and rare conditions. Vifor Pharma Group strives to help patients around the world with severe, chronic and rare diseases lead better, healthier lives. It specializes in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and includes the companies: Vifor Pharma, Sanifit Therapeutics, and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit viforpharma.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005779/en/
Contact information
Nathalie Ponnier
Global Head Corporate Communications
+41 79 957 96 73
media@viforpharma.com
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia9.6.2023 01:40:00 CEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Applications (BLAs) for the investigational treatment exagamglogene autotemcel (exa-cel) for severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The FDA has granted Priority Review for SCD and Standard Review for TDT and assigned Prescription Drug User Fee Act (PDUFA) target action dates of December 8, 2023, and March 30, 2024, respectively. Updated data from the pivotal trials supporting the regulatory submissions will be presented at the Annual European Hematology Association Congress on June 11, 2023. “We are very pleased with the acceptance of the submissions and the Priority Review designation for SCD by the FDA, as well as the progress of the exa-cel filings in the EU and U.K.,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Exa-
Citi Global Wealth Investments Issues Mid-Year Wealth Outlook 2023 - Opportunities on the Horizon: Investing Through a Slowing Economy8.6.2023 23:59:00 CEST | Press release
Citi Global Wealth Investments today released its Mid-Year Wealth Outlook 2023 report - Opportunities on the Horizon: Investing Through a Slowing Economy. This biannual report sets out Citi Global Wealth’s outlook on how investors should approach developments in the global economy, markets and geopolitics. Though 2023 has been full of extraordinary events, Citi Global Wealth sees the remainder of the year as an opportunity. We are in a “rolling recession” where parts of the US economy are growing even as others contract. As inflation slowly eases following a period of rapid Fed rate hikes, the group believes that keeping portfolios invested is imperative. While the current asset allocation strategy remains defensive, Citi Global Wealth see numerous opportunities to adjust their portfolios over time, as the Fed shifts from interest rate hikes to cuts. We believe that current markets will lead into a meaningful potential recovery in 2024. “Though the broader bear market is not yet over,
Verisign Reports Internet Has 354.0 Million Domain Name Registrations at the End of the First Quarter of 20238.6.2023 22:55:00 CEST | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of domain name registry services and internet infrastructure, today announced that the first quarter of 2023 closed with 354.0 million domain name registrations across all top-level domains (TLDs), an increase of 3.5 million domain name registrations, or 1.0%, compared to the fourth quarter of 2022.1,2 Domain name registrations also increased by 3.5 million, or 1.0%, year over year.1,2 The .com and .net TLDs had a combined total of 174.8 million domain name registrations in the domain name base3 at the end of the first quarter of 2023, an increase of 1.0 million domain name registrations, or 0.6%, compared to the fourth quarter of 2022. The .com and .net TLDs had a combined increase of 0.1 million domain name registrations, or 0.1%, year over year. As of March 31, 2023, the .com domain name base totaled 161.6 million domain name registrations, and the .net domain name base totaled 13.2 million domain name registrations. New .com and .net
Momcozy Introduces the Revolutionary M5 All-in-one Hands-free Breast Pump - Empowering Busy Moms with the Ultimate Maternity Solution8.6.2023 22:00:00 CEST | Press release
Momcozy, the esteemed maternity and baby brand favored by over two million moms worldwide, proudly unveils the revolutionary M5 all-in-one hands-free breast pump. Designed to provide the ultimate pumping experience for busy breastfeeding moms, this cutting-edge device showcases Momcozy's commitment to meeting the needs of mothers worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005079/en/ M5 All-in-one Handsfree Breast Pump (Graphic: Business Wire) Renowned for its position as a leader in the North American electric breast pump market, Momcozy distinguishes itself yet again with the M5 all-in-one hands-free breast pump. Driven by a user research team that believes in "cozy designs born from love" and strives to cater to customer needs, Momcozy has conducted extensive interviews with thousands of mothers over the past two years. The team's latest findings highlight "comfort" as the most frequently mentioned req
Mouser Electronics Explores the Intersection of Smart-Home Tech with Matter Protocol in Empowering Innovation Together Series8.6.2023 19:08:00 CEST | Press release
Mouser Electronics Inc., the industry's leading New Product Introduction (NPI) distributor with the widest selection of semiconductors and electronic components™, launches the next installment of their award-winning Empowering Innovation Together (EIT) series highlighting the Matter protocol. With this installment, Mouser brings together global technology experts from the Connectivity Standards Alliance (CSA) and industry-leading manufacturers to explore all aspects of Matter, from market introduction to design specifications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005018/en/ Matter: One protocol for them all. (Graphic: Business Wire) With its widespread industry support from leading semiconductor manufacturers, including NXP Semiconductors, Silicon Labs, STMicroelectronics, Schneider Electric, Texas Instruments, Infineon Technologies, Nordic Semiconductor and Microchip Technology Inc., Matter promises to revol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom